3️⃣ Poignant postcard: In 1912, a first-class passenger on the Titanic scrawled a message in pencil to someone back home in ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

James Manning / PA Images / Getty Images After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of ...

Novo expects CagriSema to lead to weight loss of 25%, compared with Wegovy's 15%, a result which analysts say is a must-win for Novo's obesity-tackling investment case. The Wegovy sales beat was a ...

Novo Nordisk (NVO) reported mixed earnings for the third quarter of 2024 but beat Wall Street revenue expectations for its blockbuster weight-loss drug, Wegovy. Novo announced an earnings per ...

Novo Nordisk's GLP-1 receptor agonist semaglutide ... although the severity and progressive nature of MASH makes a case for combining drugs in different classes, and the entry of new drug options ...

Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide By Robin Foster HealthDay Reporter THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and ...

Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabetes ...

MILAN (Reuters) - Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as underwhelming guidance for next year overshadowed strong ...

1 Day NVO 1.88% DJIA 0.68% S&P 500 -0.03% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...